Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Sep 14

PMID 39272837

Authors

Eszter Anna Janka

Imre Lorinc Szabo

Sandor Kollar

Tunde Toka-Farkas

Beatrix Vanyai

Tunde Varvolgyi

Aniko Kapitany

Hibah Shabu

Andrea Szegedi

Gabriella Emri

Affiliations

Soon will be listed here.

Abstract

Methods: A total of 199 patients with advanced melanoma treated with BRAF + MEK inhibitors were included in our single-center retrospective study. We analyzed the risk of progression and death using multivariate Cox proportional hazard models. The predictive effect of prognostic factors on progression-free survival (PFS) was evaluated in ROC analysis.

Results: We found that primary tumor localization, Clark level, pT category, baseline M stage and baseline serum S100B are independent and significant prognostic factors for PFS. The discriminative power of the combination of these factors was excellent for predicting 18 month PFS (AUC 0.822 [95% CI 0.727; 0.916], < 0.001). Primary tumor localization on the extremities, Clark level V, baseline M1c stage or M1d stage, and elevated baseline serum S100B and LDH levels were independently and significantly associated with unfavorable overall survival (OS).

Conclusion: Baseline M stage and serum S100B appear to be independent prognostic factors for both PFS and OS in melanoma patients treated with BRAF + MEK inhibitors. We newly identified significant and independent prognostic effects of primary tumor localization and Clark level on survival that warrant further investigation.

References

Simeone E, Grimaldi A, Festino L, Vanella V, Palla M, Ascierto P . Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. BioDrugs. 2017; 31(1):51-61. DOI: 10.1007/s40259-016-0208-z. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Ding L, Gosh A, Lee D, Emri G, Huss W, Bogner P . Prognostic biomarkers of cutaneous melanoma. Photodermatol Photoimmunol Photomed. 2022; 38(5):418-434. DOI: 10.1111/phpp.12770. View

Sandri S, Watanabe L, Oliveira E, Faiao-Flores F, Migliorini S, Tiago M . Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance. Pharmacol Res. 2020; 159:104998. DOI: 10.1016/j.phrs.2020.104998. View

Gassenmaier M, Lenders M, Forschner A, Leiter U, Weide B, Garbe C . Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. Target Oncol. 2021; 16(2):197-205. PMC: 7935737. DOI: 10.1007/s11523-021-00792-8. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Ascierto P, Dreno B, Larkin J, Ribas A, Liszkay G, Maio M . 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clin Cancer Res. 2021; 27(19):5225-5235. PMC: 9401485. DOI: 10.1158/1078-0432.CCR-21-0809. View

Hornyak L, Dobos N, Koncz G, Karanyi Z, Pall D, Szabo Z . The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy. Front Immunol. 2018; 9:151. PMC: 5797779. DOI: 10.3389/fimmu.2018.00151. View

Lattanzi M, Lee Y, Simpson D, Moran U, Darvishian F, Kim R . Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. J Natl Cancer Inst. 2018; 111(2):180-188. PMC: 7962783. DOI: 10.1093/jnci/djy086. View

10.

Park C, Kim S . Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma. Oncotarget. 2017; 8(9):14759-14769. PMC: 5362441. DOI: 10.18632/oncotarget.14736. View

11.

Ascierto P, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L . Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nat Commun. 2024; 15(1):146. PMC: 10761671. DOI: 10.1038/s41467-023-44475-6. View

12.

Robert C, Grob J, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E . Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019; 381(7):626-636. DOI: 10.1056/NEJMoa1904059. View

13.

Atkins M, Lee S, Chmielowski B, Tarhini A, Cohen G, Truong T . Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2022; 41(2):186-197. PMC: 9839305. DOI: 10.1200/JCO.22.01763. View

14.

van Wilpe S, Koornstra R, Den Brok M, De Groot J, Blank C, de Vries J . Lactate dehydrogenase: a marker of diminished antitumor immunity. Oncoimmunology. 2020; 9(1):1731942. PMC: 7051189. DOI: 10.1080/2162402X.2020.1731942. View

15.

van Zeijl M, de Wreede L, van den Eertwegh A, Wouters M, Jochems A, Schouwenburg M . Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. Eur J Cancer. 2020; 144:242-251. DOI: 10.1016/j.ejca.2020.11.028. View

16.

Janka E, Vanyai B, Szabo I, Toka-Farkas T, Varvolgyi T, Kapitany A . Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1. Front Oncol. 2023; 13:1237643. PMC: 10472446. DOI: 10.3389/fonc.2023.1237643. View

17.

Christensen E . Multivariate survival analysis using Cox's regression model. Hepatology. 1987; 7(6):1346-58. DOI: 10.1002/hep.1840070628. View

18.

Bajaj S, Donnelly D, Call M, Johannet P, Moran U, Polsky D . Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition. J Natl Cancer Inst. 2020; 112(9):921-928. PMC: 7492758. DOI: 10.1093/jnci/djaa008. View

19.

Amann V, Ramelyte E, Thurneysen S, Pitocco R, Bentele-Jaberg N, Goldinger S . Developments in targeted therapy in melanoma. Eur J Surg Oncol. 2016; 43(3):581-593. DOI: 10.1016/j.ejso.2016.10.014. View

20.

Luke J, Flaherty K, Ribas A, Long G . Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017; 14(8):463-482. DOI: 10.1038/nrclinonc.2017.43. View